Registration
 
All news
Editors' Picks
Crypto News
Financial News
Market Voices
Billionaires
Companies
Broker News
Regulators News
Ashutosh Sureka
Ashutosh Sureka

Bristol Myers Squibb wins U.S. FDA and European Commission approval for immunotherapy Hodgkin lymphoma treatment

Bristol Myers Squibb wins U.S. FDA and European Commission approval for immunotherapy Hodgkin lymphoma treatment
Bristol Myers Squibb wins Hodgkin nod

Bristol Myers Squibb has received approval from both the U.S. FDA and the European Commission for its immunotherapy-based treatment combinations targeting classical Hodgkin lymphoma in certain adult and pediatric patients.

The green light from these major regulators marks a significant milestone for Bristol Myers Squibb in the oncology space, expanding therapeutic options for those affected by this form of blood cancer. The company expects the decision to strengthen its portfolio in global cancer care.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Trading thin air: Why Binance is closing its NFT marketplace
  • By Oleg Tkachenko
  • 16 hours ago
Trading thin air: Why Binance is closing its NFT marketplace
Editors' Picks
Bitcoin without investors: Why IPOs are winning attention
  • By Eugene Komchuk
  • Yesterday
Bitcoin without investors: Why IPOs are winning attention
Editors' Picks
Bitcoin price prediction based on MACD: Bearish momentum gains strength
  • By Anastasiia Chabaniuk
  • 02.06.2026
Bitcoin price prediction based on MACD: Bearish momentum gains strength
Editors' Picks
All Editors' Top Picks

Latest Bristol Myers Squibb News

Bristol-Myers Squibb stock price forecast: short-term resistance holds as BMY slips 1.5%
  • By Oleg Tkachenko
  • 29.03.2026
Bristol-Myers Squibb stock price forecast: short-term resistance holds as BMY slips 1.5%
Companies
#Bristol Myers Squibb
Neuroscience data release drives Bristol-Myers Squibb stock lower 1.50%
  • By Ezequiel Gomes
  • 28.03.2026
Neuroscience data release drives Bristol-Myers Squibb stock lower 1.50%
Companies
#Bristol Myers Squibb
Bristol-Myers Squibb stock price forecast: consolidation likely as BMY eyes upper range resistance
  • By Hanna Syniavska
  • 27.03.2026
Bristol-Myers Squibb stock price forecast: consolidation likely as BMY eyes upper range resistance
Companies
#Bristol Myers Squibb
All Bristol Myers Squibb News
  • Oleg Tkachenko
  • 16 hours ago
Trading thin air: Why Binance is closing its NFT marketplace
  • Eugene Komchuk
  • Yesterday
Bitcoin without investors: Why IPOs are winning attention
  • Anastasiia Chabaniuk
  • 02.06.2026
Bitcoin price prediction based on MACD: Bearish momentum gains strength
  • Kyle Torpey
  • 01.06.2026
Ethereum's identity crisis: Between Wall Street and cypherpunk
  • Eugene Komchuk
  • 01.06.2026
Europe and U.S. prepare crypto taxes: How their approaches differ
  • Yulia Slavina
  • 6 min ago
Fidelity lowers SpaceX entry point to $2,000, Howard Lindzon notes
  • Yaroslav Dmytrenko
  • 15 min ago
Swift network action follows issue discovery in Zcash, Eddy Lazzarin notes
  • Hanna Syniavska
  • 20 min ago
Strike to offer liquidation-proof bitcoin-backed loans, Jack Mallers notes
  • Hlib Chabaniuk
  • 26 min ago
Arpit Gupta: No true passive index as inclusion choices always differ
  • Ashutosh Sureka
  • 31 min ago
ETF focused on S&P 500 and fast-tracked IPOs may be filed in days, Nate Geraci predicts
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Olga Shendetskaya
  • 14 hours ago
Coinbase launches SpaceX pre-IPO futures
Coinbase launches SpaceX pre-IPO futures
  • Igor Krasulya
  • 15 hours ago
S&P 500 futures fall as Iran tensions snap 9-day winning streak
S&P 500 futures fall as Iran tensions snap 9-day winning streak
  • Ivan Andriyenko
  • 16 hours ago
SpaceX IPO could lift Elon Musk's net worth above $1 trillion
SpaceX IPO could lift Elon Musk's net worth above $1 trillion
  • Anastasiia Chabaniuk
  • 17 hours ago
Coinbase freezes $3M as U.S. targets Southeast Asia scam rings
Coinbase freezes $3M as U.S. targets Southeast Asia scam rings
  • Olga Shendetskaya
  • 18 hours ago
Oil falls as Israel-Lebanon ceasefire eases Gulf risk
Oil falls as Israel-Lebanon ceasefire eases Gulf risk
Live News
  • Anton Kharitonov
  • Now
Alphabet declines amid $80 billion share issuance and AI investments
  • Anton Kharitonov
  • Now
Microsoft remains under pressure despite AI breakthroughs
  • Anton Kharitonov
  • Now
Apple pulls back after reaching new highs
  • Anton Kharitonov
  • Now
Bitcoin remains under pressure as market awaits new source of demand
  • Dmytro Kharkov
  • Now
AMD faces pullback risk as technology sector weakens
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR